Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A method of inhibiting thrombin-induced cell activation mediated by cleavage of a thrombin receptor on said cells comprising administering to an individual in need of such treatment an effective amount of a compound selected from the group consisting of: ~~comprising one or more segments having the amino acid sequence X_1-Arg-Pro-Pro-X_2, wherein the compound has a formula selected from the group consisting of:~~

~~X_1-Arg-Pro-Pro-X_2; and~~

~~L-(X_1-Arg-Pro-Pro-X_2)$_n$;~~

~~wherein:~~

~~X_1, which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids;~~

~~X_2, which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids, provided that the N-terminal amino acid of X_2 is not glycine;~~

~~L is a linker comprising a covalent bond or chemical group; and~~

~~n is an integer from two to twenty.~~

(a) Arg-Pro-Pro;

(b) Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6);

(c) Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp; and

(d)



2. (canceled).

3. (canceled.

4. (canceled).

5. (canceled).

6. (canceled).

7. (canceled).

8. (canceled).

9. (canceled).

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (currently amended) A method for preventing thrombin-induced platelet aggregation mediated by cleavage of a thrombin receptor on said platelets comprising administering to an individual in need of such treatment an effective amount of a compound selected from the group consisting of: ~~comprising one or more segments having the amino acid sequence X_1-Arg-Pro-Pro-X_2, wherein the compound has a formula selected from the group consisting of:~~

~~X_1-Arg-Pro-Pro-X_2; and~~

~~L-(X_1-Arg-Pro-Pro-X_2)$_n$;~~

~~wherein:~~

~~X_1, which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids;~~

~~X_2, which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids, provided that the N-terminal amino acid of X_2 is not glycine;~~

~~L is a linker comprising a covalent bond or chemical group; and~~

~~n is an integer from two to twenty.~~

(a) Arg-Pro-Pro;

(b) Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6);

(c) Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp; and

(d)



15. (canceled).

16. (canceled).

17. (canceled).

18. (canceled).

19. (canceled).

20. (canceled).

21. (canceled)

22. (canceled).

23. (canceled)

24. (currently amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and ~~a~~ the compound ~~comprising~~ Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6) ~~or one or more segments having the amino acid sequence X_1-Arg-Pro-Pro-X_2, wherein the compound has a formula~~

~~$L-(X_1\text{-Arg-Pro-Pro-}X_2)_n$;~~

~~wherein:~~

~~X_1, which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids;~~

~~X_2, which may be the same or different in each segment, is from zero to thirty natural or synthetic amino acids, provided that the N-terminal amino acid of X_2 is not glycine;~~

~~L is a linker comprising a covalent bond or chemical group; and~~

~~n is an integer from two to twenty~~.

25. (currently amended) ~~The~~ A pharmaceutical composition ~~of claim 24~~ comprising a pharmaceutically acceptable carrier and a compound having a formula selected from the group consisting of:

(a) Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp; and

(b)



26. (canceled).

27. (canceled).

28. (canceled)

29. (new) The method according to claim 1 wherein the compound is Arg-Pro-Pro.

30. (new) The method according to claim 1 wherein the compound is Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6).

31. (new) The method according to claim 1 wherein the compound is

Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp.

32. (new) The method according to claim 1 wherein the compound is



33. (new) The method according to claim 14 wherein the compound is Arg-Pro-Pro.

34. (new) The method according to claim 14 wherein the compound is Arg-Pro-Pro-Ala-Phe (SEQ ID NO:6).

35. (new) The method according to claim 14 wherein the compound is:

Arg-Pro-Pro-Lys
|
Arg-Pro-Pro-Asp.

36. (new) The method according to claim 14 wherein the compound is: